research MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
Search
for
Sort by
Research
390-420 / 1000+ results research Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
research Actos, slings, finasteride, and the vaccine compensation solution.
research Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
Compound 7p shows strong potential as an anticancer agent.
research Baricitinib as a treatment for myasthenia gravis: A case report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Cepharanthine Suppresses Herpes Simplex Virus Type 1 Replication Through the Downregulation of the PI3K/Akt and p38 MAPK Signaling Pathways
Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Clinical Efficacy and Cholesterol-Lowering Effects of Inclisiran
Inclisiran is effective at lowering cholesterol.
research Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
research JAK Inhibitors in the Treatment of Lichen Planopilaris
JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
research Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
research Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape
Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
research Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
research Rapid Screening of Anticoagulation Compounds for Biological Target-Associated Adverse Effects Using a Deep-Learning Framework in the Management of Atrial Fibrillation
The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research Immune reconstitution inflammatory syndrome associated with secondary syphilis: dermatologic, neurologic and ophthalmologic compromise in an HIV patient
An HIV patient with IRIS had rare syphilis symptoms affecting skin, eyes, and nerves.
research TSPO ligand etifoxine attenuates LPS-induced cognitive dysfunction in mice
Etifoxine, an anxiety drug, can lessen brain inflammation and cognitive issues in mice, partly by increasing production of protective brain steroids.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Cyclosporine a Demonstrates Bilayer Modification with Slow Kinetics
Cyclosporine A slowly changes cell membranes, explaining some of its effects and side effects.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Forsythiaside A ameliorates sepsis-induced acute kidney injury via anti-inflammation and antiapoptotic effects by regulating endoplasmic reticulum stress
Forsythiaside A reduces kidney damage from sepsis by lowering inflammation and cell death.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
research Stimulation of Hair Growth by Topical Application of FK506, a Potent Immunosuppressive Agent
research Synthesis of mimics of steroid A ring as potential enzyme inhibitors
Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.